EQRx Pronounces Acceptance of Advertising Authorization Utility by the UK’s Medicines and Healthcare Merchandise Regulatory Company for Aumolertinib in EGFR-Mutated Non-small Cell Lung Most cancers
Eqrx, Inc. Advertising authorization software is EQRx’s first submission to a regulatory company Utility is predicated on information from pivotal Section 3 AENEAS trial within the first-line remedy of EGFR-mutated non-small cell lung most cancers CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a brand new kind of pharmaceutical firm dedicated…